The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study
BackgroundPD-1/L1 inhibitor-based immunotherapy is currently under investigation in biliary tract cancer (BTC). Apatinib combined with camrelizumab has achieved promising results in various tumor types. The aim of this study was to assess the safety and efficacy of apatinib plus camrelizumab for adv...
保存先:
| 主要な著者: | , , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2021-04-01
|
| シリーズ: | Frontiers in Oncology |
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/articles/10.3389/fonc.2021.646979/full |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|